06/24/2015
For those that manage clinical trials, collecting informed consent through traditional paper-based methods is quickly becoming outdated. Electronic media offers many advantages for both patients and the advancement of scientific research.
-
In June 2025, The US Food and Drug Administration (FDA) released the final guidance titled; “Conducting Remote Regulatory Assessments Questions and Answers” to facilitate understanding about what a remote regulatory assessment (RRA) is expected from establishments when the FDA initiates or requests an RRA.
-
On June 5, 2025, the US Food and Drug Administration (FDA) issued a warning letter and FDA Form 483 to an investigator as a result of objectional conditions observed during a Bioresearch Monitoring Program (BIMO) inspection. According to the letter, the investigator did not adhere to the applicable statutory requirements of Title 21 CFR part 312.60 which states: “An investigator is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations”.
-
In February 2025 the US Food and Drug Administration (FDA) posted a series of frequently asked questions (FAQ) on their website from the public regarding Institutional Review Boards (IRB) and the protection of human subjects in research.
-
In February 2025, the US Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) Office for Human Research Protection (OHRP) released the final guidance “Institutional Review Board (IRB) Written Procedures.”
-
In the ever changing world of clinical research, staying up to date with the latest guidelines and best practices is crucial. Our Major Changes in GCP from ICH E6(R2) to (R3): Road Map is designed for busy professionals who want to deepen their knowledge on GCP to help ensure they meet the highest standards of quality, safety, and compliance.
Promeditec has developed a package that enables the user to carry out remote monitoring of clinical trials. Virtual On Site Monitoring (VOS) integrates high-cost traditional monitoring with an innovative method that leads to significant reduction in time and cost by eliminating the need for monitor relocation.
Monitoring clinical data is a critical part of trial success. Part of doing this effectively is efficiency, so a question being asked more frequently is “why not monitor source data remotely?” This course discusses the feasibility of remote monitoring of source data in compliance with predicate rules, including HIPAA, FDA, as well as mandates outside the US.